Published in Mol Genet Metab on July 01, 2002
Clinical and Basic Investigations Into Hermansky-Pudlak Syndrome | NCT00001456
Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome | NCT00001596
Disorders of lysosome-related organelle biogenesis: clinical and molecular genetics. Annu Rev Genomics Hum Genet (2008) 2.83
Pirfenidone for diabetic nephropathy. J Am Soc Nephrol (2011) 2.04
Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS One (2007) 1.88
Hermansky-Pudlak syndrome type 4 (HPS-4): clinical and molecular characteristics. Hum Genet (2003) 1.69
A new hypothesis about the origin of uterine fibroids based on gene expression profiling with microarrays. Am J Obstet Gynecol (2006) 1.60
Interstitial lung disease and pulmonary fibrosis in Hermansky-Pudlak syndrome type 2, an adaptor protein-3 complex disease. Mol Med (2012) 1.26
Susceptibility of Hermansky-Pudlak mice to bleomycin-induced type II cell apoptosis and fibrosis. Am J Respir Cell Mol Biol (2007) 1.20
Alveolar macrophage dysregulation in Hermansky-Pudlak syndrome type 1. Am J Respir Crit Care Med (2009) 1.15
Pirfenidone for the treatment of Hermansky-Pudlak syndrome pulmonary fibrosis. Mol Genet Metab (2011) 1.13
Genetic testing for oculocutaneous albinism type 1 and 2 and Hermansky-Pudlak syndrome type 1 and 3 mutations in Puerto Rico. J Invest Dermatol (2006) 1.12
Epithelial stress and apoptosis underlie Hermansky-Pudlak syndrome-associated interstitial pneumonia. Am J Respir Crit Care Med (2010) 1.10
The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial. Respir Res (2011) 1.06
Hermansky-pudlak syndrome: report of a case and review of the literature. Int J Clin Exp Pathol (2008) 1.01
The multifaceted role of pirfenidone and its novel targets. Fibrogenesis Tissue Repair (2010) 1.00
Pirfenidone modulates airway responsiveness, inflammation, and remodeling after repeated challenge. Am J Respir Cell Mol Biol (2006) 0.99
Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. Respir Res (2011) 0.98
Clinical and cellular characterisation of Hermansky-Pudlak syndrome type 6. J Med Genet (2009) 0.98
Dysregulation of galectin-3. Implications for Hermansky-Pudlak syndrome pulmonary fibrosis. Am J Respir Cell Mol Biol (2014) 0.96
A mutation in Rab38 small GTPase causes abnormal lung surfactant homeostasis and aberrant alveolar structure in mice. Am J Pathol (2008) 0.96
Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapy. Treat Respir Med (2006) 0.90
Glucose transporter-1 distribution in fibrotic lung disease: association with [¹⁸F]-2-fluoro-2-deoxyglucose-PET scan uptake, inflammation, and neovascularization. Chest (2013) 0.90
Adverse events of pirfenidone for the treatment of pulmonary fibrosis: a meta-analysis of randomized controlled trials. PLoS One (2012) 0.89
Genetic interstitial lung disease. Clin Chest Med (2011) 0.89
Respiratory symptoms and disease characteristics as predictors of pulmonary function abnormalities in patients with rheumatoid arthritis: an observational cohort study. Arthritis Res Ther (2010) 0.88
Hermansky-Pudlak syndrome: the importance of molecular subtyping. J Thromb Haemost (2010) 0.88
Pirfenidone: an anti-fibrotic therapy for progressive kidney disease. Expert Opin Investig Drugs (2010) 0.88
The treatment of idiopathic pulmonary fibrosis. F1000Prime Rep (2014) 0.86
Oral pirfenidone in patients with chronic fibrosis resulting from radiotherapy: a pilot study. Radiat Oncol (2007) 0.84
Hermansky-Pudlak syndrome type 4 with interstitial pneumonia. Respir Med Case Rep (2013) 0.83
Clinical, molecular, and cellular features of non-Puerto Rican Hermansky-Pudlak syndrome patients of Hispanic descent. J Invest Dermatol (2011) 0.81
Hermansky-Pudlak syndrome in two African-American brothers. Am J Med Genet A (2009) 0.79
Hermansky-Pudlak syndrome type 1 in patients of Indian descent. Mol Genet Metab (2009) 0.77
Pulmonary Fibrosis in Hermansky-Pudlak Syndrome. Ann Am Thorac Soc (2016) 0.76
Hermansky-Pudlak syndrome in the peripartum period. Obstet Med (2008) 0.75
Hermansky-Pudlak Syndrome. Clin Chest Med (2016) 0.75
A case of hermansky-pudlak syndrome with pulmonary sarcoidosis. J Clin Aesthet Dermatol (2009) 0.75
Case Report : Hermansky Pudlak Syndrome (Presenting as late onset heavy Menstrual Bleeding). J Clin Diagn Res (2013) 0.75
Contemporary cesarean delivery practice in the United States. Am J Obstet Gynecol (2010) 5.00
The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med (2005) 4.15
Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. Hum Mutat (2007) 3.93
Respiratory morbidity in late preterm births. JAMA (2010) 3.11
Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med (2008) 3.04
The natural history of the normal first stage of labor. Obstet Gynecol (2010) 2.85
Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: interim results. Hum Gene Ther (2011) 2.75
Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis (2003) 2.73
Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. Am J Respir Crit Care Med (2007) 2.68
Contemporary patterns of spontaneous labor with normal neonatal outcomes. Obstet Gynecol (2010) 2.62
Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother (2002) 2.30
Acute fibrinous and organizing pneumonia: a histological pattern of lung injury and possible variant of diffuse alveolar damage. Arch Pathol Lab Med (2002) 2.11
Appropriateness of newborn screening for α1-antitrypsin deficiency. J Pediatr Gastroenterol Nutr (2014) 2.10
Maternal obesity and congenital heart defects: a population-based study. Am J Clin Nutr (2010) 2.06
Single nucleotide polymorphism-mediated translational suppression of endoplasmic reticulum mannosidase I modifies the onset of end-stage liver disease in alpha1-antitrypsin deficiency. Hepatology (2009) 2.03
A 3-year randomized therapeutic trial of nitisinone in alkaptonuria. Mol Genet Metab (2011) 1.98
Early interstitial lung disease in familial pulmonary fibrosis. Am J Respir Crit Care Med (2007) 1.91
Using a simplified Bishop score to predict vaginal delivery. Obstet Gynecol (2011) 1.83
Maximal oxygen uptake and severity of disease in lymphangioleiomyomatosis. Am J Respir Crit Care Med (2003) 1.78
Healthy People 2010: challenges, opportunities, and a call to action for America's pharmacists. Pharmacotherapy (2004) 1.71
Pneumothorax after air travel in lymphangioleiomyomatosis, idiopathic pulmonary fibrosis, and sarcoidosis. Chest (2009) 1.64
Maternal and neonatal outcomes by labor onset type and gestational age. Am J Obstet Gynecol (2010) 1.54
Prepregnancy risk factors for antepartum stillbirth in the United States. Obstet Gynecol (2010) 1.53
The maternal body mass index: a strong association with delivery route. Am J Obstet Gynecol (2010) 1.52
A comparison of obstetric maneuvers for the acute management of shoulder dystocia. Obstet Gynecol (2011) 1.51
Characteristics associated with severe perineal and cervical lacerations during vaginal delivery. Obstet Gynecol (2011) 1.45
Hermansky-Pudlak syndrome: radiography and CT of the chest compared with pulmonary function tests and genetic studies. AJR Am J Roentgenol (2002) 1.45
Phylogenetic lineages of invasive and colonizing strains of serotype III group B Streptococci from neonates: a multicenter prospective study. J Clin Microbiol (2006) 1.41
Level of maternal IgG anti-group B streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen. J Infect Dis (2004) 1.36
Meeting the needs of young women with secondary amenorrhea and spontaneous premature ovarian failure. Obstet Gynecol (2002) 1.33
Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. Chest (2009) 1.28
Contemporary labor patterns: the impact of maternal body mass index. Am J Obstet Gynecol (2011) 1.26
Endothelial alpha-1-antitrypsin attenuates cigarette smoke induced apoptosis in vitro. COPD (2008) 1.25
Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression. J Clin Invest (2013) 1.20
Zoledronic acid and secondary prevention of fractures. N Engl J Med (2007) 1.19
Influence of serum leptin on weight and body fat growth in children at high risk for adult obesity. J Clin Endocrinol Metab (2006) 1.16
A common variant in MTHFD1L is associated with neural tube defects and mRNA splicing efficiency. Hum Mutat (2009) 1.15
Pirfenidone for the treatment of Hermansky-Pudlak syndrome pulmonary fibrosis. Mol Genet Metab (2011) 1.13
Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis. Antimicrob Agents Chemother (2009) 1.11
The 19-bp deletion polymorphism in intron-1 of dihydrofolate reductase (DHFR) may decrease rather than increase risk for spina bifida in the Irish population. Am J Med Genet A (2007) 1.05
Popcorn calcification in osteogenesis imperfecta: incidence, progression, and molecular correlation. Am J Med Genet A (2008) 1.05
Automated quantification of high-resolution CT scan findings in individuals at risk for pulmonary fibrosis. Chest (2011) 1.03
In vivo post-transcriptional gene silencing of alpha-1 antitrypsin by adeno-associated virus vectors expressing siRNA. Lab Invest (2007) 1.03
NIH conference. Future directions in the study and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Ann Intern Med (2002) 1.03
Choline concentrations in human maternal and cord blood and intelligence at 5 y of age. Am J Clin Nutr (2008) 1.01
Bone formation in transplants of human bone marrow stromal cells and hydroxyapatite-tricalcium phosphate: prediction with quantitative CT in mice. Radiology (2004) 1.01
Genetic and morphologic determinants of pneumothorax in lymphangioleiomyomatosis. Am J Physiol Lung Cell Mol Physiol (2007) 1.01
The challenge of detecting alpha-1 antitrypsin deficiency. COPD (2013) 1.00
Waist circumference, BMI, and visceral adipose tissue in white women and women of African descent. Obesity (Silver Spring) (2010) 1.00
Prematurity is the major risk factor for late-onset group B streptococcus disease. J Infect Dis (2003) 1.00
Accelerated spirometric decline in New York City firefighters with α₁-antitrypsin deficiency. Chest (2010) 0.99
Metabolic syndrome traits in long-term survivors of pediatric sarcoma. Pediatr Blood Cancer (2008) 0.96
Selective reduction in cortical bone mineral density in turner syndrome independent of ovarian hormone deficiency. J Clin Endocrinol Metab (2003) 0.94
Treatment of metastatic osteosarcoma with the somatostatin analog OncoLar: significant reduction of insulin-like growth factor-1 serum levels. J Pediatr Hematol Oncol (2002) 0.94
Construction of a high resolution linkage disequilibrium map to evaluate common genetic variation in TP53 and neural tube defect risk in an Irish population. Am J Med Genet A (2008) 0.92
Natural history of fetal position during pregnancy and risk of nonvertex delivery. Obstet Gynecol (2008) 0.90
Nuclear localization of active matrix metalloproteinase-2 in cigarette smoke-exposed apoptotic endothelial cells. Exp Lung Res (2009) 0.90
The physical phenotype of girls and women with Turner syndrome is not X-imprinted. Hum Genet (2007) 0.89
Biochemical efficacy and safety of a new pooled human plasma alpha(1)-antitrypsin, Respitin. Chest (2002) 0.89
Pyrimethamine treatment does not ameliorate lymphoproliferation or autoimmune disease in MRL/lpr-/- mice or in patients with autoimmune lymphoproliferative syndrome. Am J Hematol (2007) 0.89
Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother (2004) 0.87
Efficient and accurate approaches to the laboratory diagnosis of alpha1-antitrypsin deficiency: The promise of early diagnosis and intervention. Clin Chem (2006) 0.87
Analysis of the MTHFD1 promoter and risk of neural tube defects. Hum Genet (2009) 0.87
Isolated oligohydramnios is not associated with adverse perinatal outcomes. BJOG (2004) 0.86
Circulating polymers in α1-antitrypsin deficiency. Eur Respir J (2014) 0.85
Primary care diagnosis of alpha-1 antitrypsin deficiency: issues and opportunities. Cleve Clin J Med (2007) 0.85
Multidimensional volumetric imaging of pulmonary infiltrates for measuring therapeutic response to antifungal therapy in experimental invasive pulmonary aspergillosis. Antimicrob Agents Chemother (2006) 0.84
Uncoupling protein 2 polymorphisms as risk factors for NTDs. Birth Defects Res A Clin Mol Teratol (2009) 0.84
A prospective cohort study of the prevalence of growth, facial, and central nervous system abnormalities in children with heavy prenatal alcohol exposure. Alcohol Clin Exp Res (2012) 0.83
Use of PET/CT with cosyntropin stimulation to identify and localize adrenal rest tissue following adrenalectomy in a woman with congenital adrenal hyperplasia. J Clin Endocrinol Metab (2012) 0.83
Pharmacology and antifungal properties of anidulafungin, a new echinocandin. Pharmacotherapy (2009) 0.82
Risk factors for birth canal lacerations in primiparous women. Am J Perinatol (2008) 0.81
Liver test results do not identify liver disease in adults with α(1)-antitrypsin deficiency. Clin Gastroenterol Hepatol (2012) 0.81
Markers of oxidative stress and systemic vasoconstriction in pregnant women drinking > or =48 g of alcohol per day. Alcohol Clin Exp Res (2008) 0.81
Reprogramming adipose tissue-derived mesenchymal stem cells into pluripotent stem cells by a mutant adeno-associated viral vector. Hum Gene Ther Methods (2013) 0.81
More on ovarian insufficiency with imatinib. N Engl J Med (2008) 0.79
Multi-center study: the biochemical efficacy, safety and tolerability of a new alpha1-proteinase inhibitor, Zemaira. COPD (2006) 0.78
Heavy prenatal alcohol exposure and risk of stillbirth and preterm delivery. J Matern Fetal Neonatal Med (2011) 0.78
Pharmacists and emergency contraception. N Engl J Med (2005) 0.78
Alpha-1 antitrypsin augmentation therapy and biomarkers of elastin degradation. COPD (2013) 0.78
Is PiSS Alpha-1 Antitrypsin Deficiency Associated with Disease? Pulm Med (2010) 0.78
The prevalence of diabetes mellitus in the parents of women with Turner's syndrome. Clin Endocrinol (Oxf) (2004) 0.77
Phenotypic profiling of parents with cryptic nonclassic congenital adrenal hyperplasia: findings in 145 unrelated families. Eur J Endocrinol (2011) 0.77
Genotyping of a tri-allelic polymorphism by a novel melting curve assay in MTHFD1L: an association study of nonsyndromic Cleft in Ireland. BMC Med Genet (2012) 0.77
Biochemical efficacy and safety of a new, ready-to-use, liquid alpha-1-proteinase inhibitor, GLASSIA (alpha1-proteinase inhibitor (human), intravenous). COPD (2013) 0.76
Thioredoxin as a biomarker for graft rejection in lung transplant recipients. Biomarkers (2008) 0.76
Immunologic, virologic, and neuropsychologic responses in human immunodeficiency virus-infected children receiving their first highly active antiretroviral therapy regimen. Viral Immunol (2007) 0.76
Effects of prenatal ethanol exposure on postnatal growth and the insulin-like growth factor axis. Horm Res Paediatr (2010) 0.76
Prevalence of uterine leiomyomas in lymphangioleiomyomatosis. Fertil Steril (2011) 0.76
Fetal growth and timing of parturition in humans. Am J Epidemiol (2008) 0.75
Comment: pharmacist critique was ill-informed. Ann Pharmacother (2006) 0.75
Photocatalytic degradation of paracetamol: intermediates and total reaction mechanism. J Hazard Mater (2012) 0.75
Additive gastrointestinal effects with concomitant use of olestra and orlistat. Ann Pharmacother (2002) 0.75
Secretin available under FDA treatment protocol. Am J Health Syst Pharm (2002) 0.75
Emergency contraception: the right to full disclosure. Am J Health Syst Pharm (2004) 0.75
Using Organizational Philosophy to Create a Self-Sustaining Compensation Plan Without Harming Academic Missions. Acad Med (2017) 0.75
Extracorporeal removal of antimicrobials during plasmapheresis. J Clin Apher (2003) 0.75